Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue-Reference-Cited by-同舟云学术

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

Published:2022-04-01 Issue:4 Volume:8 Page:607
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Fernandez Aileen I.¹,Liu Matthew¹,Bellizzi Andrew²,Brock Jane³,Fadare Oluwole⁴,Hanley Krisztina⁵,Harigopal Malini¹,Jorns Julie M.⁶,Kuba M. Gabriela⁷,Ly Amy⁸,Podoll Mirna⁹,Rabe Kimmie¹⁰,Sanders Mary Ann¹¹,Singh Kamaljeet¹²,Snir Olivia L.¹³,Soong T. Rinda¹⁴,Wei Shi¹⁵,Wen Hannah⁷,Wong Serena¹,Yoon Esther¹⁶,Pusztai Lajos¹⁷,Reisenbichler Emily¹,Rimm David L.¹¹⁷

Affiliation:

1. Department of Pathology, Yale University School of Medicine, New Haven, Connecticut

2. Department of Pathology, The University of Iowa, Iowa City

3. Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

4. Department of Pathology, University of California, San Diego

5. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia

6. Department of Pathology, Medical College of Wisconsin, Milwaukee

7. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

8. Department of Pathology, Massachusetts General Hospital, Boston

9. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee

10. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis

11. Department of Pathology, Norton Healthcare, Louisville, Kentucky

12. Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island

13. Department of Pathology, Oregon Health & Science University, Portland

14. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

15. Department of Pathology, University of Alabama at Birmingham

16. Department of Pathology, MD Anderson Cancer Center, Houston, Texas

17. Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2788567/jamaoncology_fernandez_2022_br_210019_1662060014.04204.pdf

Reference7 articles.

1. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.;Doi;Lancet Oncol,2017

2. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib Study.;Modi;J Clin Oncol,2020

3. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.;McCabe;J Natl Cancer Inst,2005

4. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.;Onsum;Am J Pathol,2013

5. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.;Wolff;Arch Pathol Lab Med,2007

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges;Journal of Pathology Informatics;2024-12

2. The Emergence of the Potential Therapeutic Targets: Ultrasound-Based Radiomics in the Prediction of Human Epidermal Growth Factor Receptor 2-Low Breast Cancer;Academic Radiology;2024-02

3. Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer;Modern Pathology;2024-02

4. Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma;Journal of Nuclear Medicine;2024-02

5. A gene expression-based classifier for HER2-low breast cancer;Scientific Reports;2024-02-01